Notably, Crizotinib, Bosutinib, and Ponatinib, were identified as NET inducers and may, therefore, have application for treating NET-deficiency in patients such as those with CGD (4); indeed and importantly, data indicate that their intracellular targets modulate NET formation downstream of the NADPH-Oxidase components. The gene discussed is FMO5; the disease is chronic granulomatous disease.